The 36-month beta value for KURA is also noteworthy at 0.76. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for KURA is 65.25M, and at present, short sellers hold a 16.91% of that float. The average trading volume of KURA on December 04, 2024 was 1.19M shares.
KURA) stock’s latest price update
Kura Oncology Inc (NASDAQ: KURA) has experienced a decline in its stock price by -1.34 compared to its previous closing price of 11.17. However, the company has seen a gain of 2.51% in its stock price over the last five trading days. globenewswire.com reported 2024-12-02 that Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH
KURA’s Market Performance
Kura Oncology Inc (KURA) has seen a 2.51% rise in stock performance for the week, with a -38.12% decline in the past month and a -44.00% plunge in the past quarter. The volatility ratio for the week is 4.91%, and the volatility levels for the past 30 days are at 7.22% for KURA. The simple moving average for the past 20 days is -22.85% for KURA’s stock, with a -43.81% simple moving average for the past 200 days.
Analysts’ Opinion of KURA
Many brokerage firms have already submitted their reports for KURA stocks, with UBS repeating the rating for KURA by listing it as a “Buy.” The predicted price for KURA in the upcoming period, according to UBS is $27 based on the research report published on October 24, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see KURA reach a price target of $19, previously predicting the price at $26. The rating they have provided for KURA stocks is “Hold” according to the report published on October 14th, 2024.
Mizuho gave a rating of “Buy” to KURA, setting the target price at $26 in the report published on December 22nd of the previous year.
KURA Trading at -33.44% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.41% of loss for the given period.
Volatility was left at 7.22%, however, over the last 30 days, the volatility rate increased by 4.91%, as shares sank -37.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.63% lower at present.
During the last 5 trading sessions, KURA rose by +2.09%, which changed the moving average for the period of 200-days by -45.88% in comparison to the 20-day moving average, which settled at $14.28. In addition, Kura Oncology Inc saw -23.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from FORD KATHLEEN, who sale 526 shares at the price of $16.03 back on Nov 18 ’24. After this action, FORD KATHLEEN now owns 23,184 shares of Kura Oncology Inc, valued at $8,434 using the latest closing price.
FORD KATHLEEN, the Officer of Kura Oncology Inc, proposed sale 526 shares at $15.99 during a trade that took place back on Nov 18 ’24, which means that FORD KATHLEEN is holding shares at $8,410 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -171.26 for the present operating margin
- 0.49 for the gross margin
The net margin for Kura Oncology Inc stands at -155.55. The total capital return value is set at -0.5. Equity return is now at value -46.28, with -41.48 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -17.85. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -135.09.
Currently, EBITDA for the company is -164.96 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 647.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.47.
Conclusion
In summary, Kura Oncology Inc (KURA) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
